161 related articles for article (PubMed ID: 36964411)
1. Significance of Dynamic Changes of VCA-IgA Levels in Pre- and Post-treatment Plasma of Patients with Nasopharyngeal Carcinoma: Development of a Clinically-Oriented Model.
Mao M; Sheng H; Tian B; Chi P; Huang K; Li H; Liu W
Adv Ther; 2023 May; 40(5):2426-2438. PubMed ID: 36964411
[TBL] [Abstract][Full Text] [Related]
2. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
4. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
5. Plasma Macrophage Inhibitory Cytokine-1 as a Complement of Epstein-Barr Virus Related Markers in Identifying Nasopharyngeal Carcinoma.
Xing S; Li H; Pi Y; Zeng T; Huang Q; Ou G; Xue N
Technol Cancer Res Treat; 2020; 19():1533033820956991. PubMed ID: 33025864
[TBL] [Abstract][Full Text] [Related]
6. A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma.
Liu W; Li H; Sheng H; Liu X; Chi P; Wang X; Mao M
Adv Ther; 2020 Oct; 37(10):4280-4290. PubMed ID: 32780356
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
[TBL] [Abstract][Full Text] [Related]
8. Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA.
Xue N; Lin JH; Xing S; Liu D; Li SB; Lai YZ; Wang XP; Mao MJ; Zhong Q; Zeng MS; Liu WL
Cancer Res Treat; 2019 Jan; 51(1):378-390. PubMed ID: 29807404
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
Ling W; Cao SM; Huang QH; Li YH; Deng MQ
Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
[TBL] [Abstract][Full Text] [Related]
10. Exosomal cyclophilin A as a novel noninvasive biomarker for Epstein-Barr virus associated nasopharyngeal carcinoma.
Liu L; Zuo L; Yang J; Xin S; Zhang J; Zhou J; Li G; Tang J; Lu J
Cancer Med; 2019 Jun; 8(6):3142-3151. PubMed ID: 31063269
[TBL] [Abstract][Full Text] [Related]
11. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Value of Serum Epstein-Barr Virus Capsid Antigen-IgA for Nasopharyngeal Carcinoma: a Meta-Analysis Based on 21 Studies.
Chen Y; Xin X; Cui Z; Zheng Y; Guo J; Chen Y; Lin Y; Su G
Clin Lab; 2016; 62(6):1155-66. PubMed ID: 27468579
[TBL] [Abstract][Full Text] [Related]
13. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
Luo YL; Chen H; Peng SG; Lin JH; Huang PY
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
[TBL] [Abstract][Full Text] [Related]
14. The interaction and mediation effects between the host genetic factors and Epstein-Barr virus VCA-IgA in the risk of nasopharyngeal carcinoma.
Diao H; Xue WQ; Wang TM; Yang DW; Deng CM; Li DH; Zhang WL; Liao Y; Wu YX; Chen XY; Zhou T; Li XZ; Zhang PF; Zheng XH; Zhang SD; Hu YZ; Cao SM; Liu Q; Ye WM; He YQ; Jia WH
J Med Virol; 2023 Nov; 95(11):e29224. PubMed ID: 37970759
[TBL] [Abstract][Full Text] [Related]
15. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
[TBL] [Abstract][Full Text] [Related]
16. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma.
Tang LQ; Li CF; Li J; Chen WH; Chen QY; Yuan LX; Lai XP; He Y; Xu YX; Hu DP; Wen SH; Peng YT; Zhang L; Guo SS; Liu LT; Guo L; Wu YS; Luo DH; Huang PY; Mo HY; Xiang YQ; Sun R; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Cao KJ; Qian CN; Guo X; Zeng YX; Mai HQ; Zeng MS
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26467665
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
[TBL] [Abstract][Full Text] [Related]
18. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic significance of serum anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma].
Cai YL; Li J; Lu AY; Zhong WM; Zheng YM; Gao JQ; Zeng H; Chen WS; Liang W; Tang MZ
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr; 27(2):119-22. PubMed ID: 24044217
[TBL] [Abstract][Full Text] [Related]
20. Heat Shock Protein 90α Provides an Effective and Novel Diagnosis Strategy for Nasopharyngeal Carcinoma.
Mao M; Wang X; Sheng H; Li H; Liu W; Han R; Wen W; Liu W
Adv Ther; 2021 Jan; 38(1):413-422. PubMed ID: 33141414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
